Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

Nektar Therapeutics

We are investigating Nektar Therapeutics (NKTR) (“Nektar” or the “Company”) for potential violations of the federal securities laws.

On August 8, 2019, after the market closed, Nektar revealed that a manufacturing issue caused two batches of NKTR-214 (bempegaldesleukin), the Company’s lead immune-oncology candidate, to differ from the other 20 batches that were produced. Moreover, these batches resulted in variable clinical benefit than other batches used in Nektar’s PIVOT-02 clinical trial. On this news, Nektar’s stock price fell $8.65 per share, or 29.25%, to close at $20.92 per share on August 9, 2019.